On Friday, GoPro Inc (NASDAQ:GPRO)’s shares inclined 1.70% to $19.15.
GoPro, Inc. ( GPRO) declared the launch of Apple Watch features in the GoPro App for iOS to enable quick access to the camera’s controls right from the wrist. This new app allows users to preview their shot, toggle between capture modes, start/stop record and add HiLight Tags to the best moments of their videos.
In addition to the Apple Watch integration, the latest version of the GoPro App offers a new design and makes capturing and sharing easier by allowing users to grab high-quality still images from videos, filter media by photo, video or HiLighted moments, and continue to use the app’s Trim & Share features to produce 5-second, 15-second and 30-second clips.
GoPro App for iOS - Apple Watch Features:
- Preview shots
- Start / stop record
- Change capture modes
- Add HiLight Tag
GoPro App Updates for both iOS and Android Devices:
- Grab photos from videos:Quickly flip through a video frame-by-frame to find that epic moment and download a high-quality still image.
- Find your media faster:Locate that awesome shot by filtering your media to display only photos, videos, HiLight Tags or clips.
To learn more about GoPro’s Apple Watch features and other brand new updates to the GoPro App, visit the GoPro news blog, The Inside Line.
GoPro, Inc. develops hardware and software solutions to alleviate consumer pain points associated with capturing, managing, sharing, and enjoying engaging content. The company offers HERO line of capture devices, such as cameras; premium accessories, counting battery BacPac, smart remote, and LCD touch BacPac accessories; and mounts comprising equipment-based mounts comprising of helmet, handlebar, roll bar, and grip and tripod mounts that enable consumers to capture content while engaged in a range of activities, in addition to mounts that enable customers to wear the mount on their bodies, such as wrist housings, chest harnesses, and head straps.
Nektar Therapeutics (NASDAQ:NKTR)’s shares dropped -2.40% to $15.45.
Nektar Therapeutics, declared that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate the beta and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).
The Phase 1/2 study of NKTR-214 is designed to evaluate patients with advanced solid tumors, counting melanoma, renal cell carcinoma and non-small cell lung cancer. The study is being conducted initially at two primary investigator sites: MD Anderson Cancer Center under Drs. Patrick Hwu and Adi Diab; and Yale Cancer Center, under Drs. Mario Sznol and Michael Hurwitz.
NKTR-214 is designed to be administered similarly to the dosing plans for approved PD-1 and CTLA-4 agents, and will be evaluated on a once every three week dosing plan in the Phase 1/2 clinical trial. In preclinical studies, NKTR-214 demonstrated a mean ratio of 450:1 within the tumor micro-environment of CD8-positive effector T-cells, which promote tumor killing, contrast with CD4-positive regulatory T cells, which are a type of cell that can suppress tumor killing.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.
At the end of Friday’s trade, Herbalife Ltd. (NYSE:HLF)‘s shares dipped -2.28% to $54.11.
Global nutrition company, Herbalife (HLF), declared that Michael Johnson, Herbalife’s chairman and CEO, has engaged in a net exercise transaction involving 280,000 stock appreciation rights (SARs) that were due to expire in March 2016. Because of his complete confidence in the continued and future success of the company, Mr. Johnson has decided that he will hold all the shares issued on exercise of these awards, which will be the total amount, net of those necessary to cover the exercise price and any taxes related to the transaction.
Herbalife Ltd., a nutrition company, develops and sells weight administration, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products.